Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead Sciences has made significant strides in both HIV prevention and oncology sectors. The company's HIV drug, lenacapavir, showed a 96% reduction in HIV infections in a Phase 3 trial, ...